ROI Financial Advisors LLC Has $2.02 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

ROI Financial Advisors LLC increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,997 shares of the company’s stock after buying an additional 64 shares during the period. IDEXX Laboratories accounts for approximately 1.4% of ROI Financial Advisors LLC’s investment portfolio, making the stock its 19th biggest position. ROI Financial Advisors LLC’s holdings in IDEXX Laboratories were worth $2,019,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IDXX. Chicago Partners Investment Group LLC raised its stake in IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock valued at $340,000 after acquiring an additional 96 shares during the period. Manning & Napier Advisors LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $20,418,000. Oppenheimer Asset Management Inc. grew its stake in IDEXX Laboratories by 13.8% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company’s stock valued at $5,825,000 after buying an additional 1,453 shares during the last quarter. Vanguard Group Inc. raised its holdings in IDEXX Laboratories by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company’s stock valued at $4,576,476,000 after acquiring an additional 98,387 shares during the period. Finally, National Pension Service grew its stake in shares of IDEXX Laboratories by 7.3% in the third quarter. National Pension Service now owns 185,972 shares of the company’s stock valued at $93,957,000 after acquiring an additional 12,647 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on IDXX shares. JPMorgan Chase & Co. cut their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. BTIG Research began coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. Piper Sandler reiterated a “neutral” rating and set a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Finally, Barclays cut their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $552.38.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $429.82 on Thursday. The stock has a 50 day moving average of $471.09 and a 200 day moving average of $484.18. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 12 month low of $404.74 and a 12 month high of $583.39. The company has a market capitalization of $35.20 billion, a price-to-earnings ratio of 41.45, a PEG ratio of 3.72 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company’s revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.53 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.